Home › Crohn's Disease › Colorado
Crohn's Disease clinical trials in Colorado
18 studies for Crohn's Disease are looking for participants at sites in Colorado.
Cities in Colorado
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 280507, Colorado Springs
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 5, 2026 · NCT07697456A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 5026), Aurora
- Peak Gastroenterology Associates ( Site 5023), Colorado Springs
- South Denver Gastroenterology, PC ( Site 5132), Englewood
- and 1 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Peak Gastroenterology Associates, Colorado Springs
- Rocky Mountain Endocopy Centers LLC, Littleton
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 265557, Colorado Springs
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UCHealth Digestive Health Center - Anschutz Medical Campus-Site Number: 8400085, Aurora
- Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado Springs
- Gastroenterology of the Rockies - Denver-Site Number: 8400122, Denver
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado Springs
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Children's Hospital Colorado - Aurora /ID# 255764, Aurora
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- South Denver Gastroenterology, Englewood
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483099A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates - Colorado Springs, Colorado Springs
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 22, 2026 · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- South Denver Gastroenterology, Englewood
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483073A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577843Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Colorado, Aurora
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Children's Hospital Colorado - Aurora /ID# 262207, Aurora
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated May 27, 2026 · NCT06227910Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Colorado Springs
- Mirador Therapeutics Selected Site, Littleton
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.